|
Purusing the ASCO website, I found an abstract from their meeting which stated that Taxol given weekly is superior to every three weeks for metastatic BC patients. This was included with Herceptin for HER2 pos. women and with and without Herceptin for HER2 neg. While it stated a 40% response rate for weekly doses vs. a 28% response rate for 3 week doses, it didn't go into detail about that.
Love and light,
Lisa
|
Threaded Mode